Related Experiment Video
Updated: Apr 14, 2026

Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct
Published on: April 1, 2022
Emergent triglyceride-lowering therapy for hypertriglyceridemic pancreatitis
Emergent triglyceride-lowering therapies are crucial for managing hypertriglyceridemic pancreatitis (HTGP). Insulin, heparin, therapeutic plasma exchange, and double-filtration offer rapid triglyceride reduction, with potential adjuvant therapies for long-term control.
Area of Science:
- Endocrinology
- Gastroenterology
- Critical Care Medicine
Background:
- Hypertriglyceridemia (HTG) is a primary cause of severe acute pancreatitis.
- Hypertriglyceridemic pancreatitis (HTGP) often presents with significant complications.
- Rapid reduction of serum triglyceride (TG) levels is essential for managing HTGP.
Purpose of the Study:
- To review emergent triglyceride-lowering therapies for hypertriglyceridemic pancreatitis.
- To evaluate the advantages and controversies of these rapid triglyceride-lowering treatments.
- To identify potential adjuvant therapies for long-term HTGP management.
Main Methods:
- Literature search of PubMed and MEDLINE databases.
- Keywords included "hypertriglyceridemia", "hyperlipidemia", and "pancreatitis".
- Search conducted up to September 2012.
Main Results:
- Insulin offers a non-invasive, economical, and safe option, though its efficiency is limited.
- Combination therapy with insulin and low molecular weight heparin (LMWH) is a viable early-stage treatment.
- Therapeutic plasma exchange (TPE) and double-filtration (DF) directly remove pathogenic substances but are costly and less accessible.
- Potential adjuvant therapies include medium chain triglycerides, omega-3 fatty acids, fibrates, niacin, microsomal transport protein inhibitors, and gene therapy.
Conclusions:
- Insulin, insulin combined with LMWH, TPE, and DF are established emergent therapies for HTGP.
- Adjuvant therapies show promise for achieving permanent control of HTGP.
- Further research into novel and combination therapies is warranted for optimal HTGP management.
Related Concept Videos
Acute Pancreatitis II: Clinical Manifestations and Management
Chronic Pancreatitis II: Collaborative Care
Assessment:
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents

